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Tumour development driven by 
inflammation is now an established phenomenon 
but the role that complement plays remains 
uncertain. Recent evidence has suggested that 
various components of the complement (C) 
cascade may influence tumour development in 
disparate ways; however, little attention has been 
paid to that of the membrane attack complex 
(MAC). This is despite abundant evidence 
documenting the effects of this complex on cell 
behaviour, including cell activation, protection 
from/induction of apoptosis, release of 
inflammatory cytokines, growth factors and ECM 
components and regulators and the triggering of 
the NLRP3 inflammasome. Here we present a 
novel approach to this issue by using global gene 
expression studies in conjunction with a systems 
biology analysis. Using network analysis of MAC 
responsive expression changes we demonstrate a 
cluster of co-regulated genes known to have 
impact in the extracellular space and on the 
supporting stroma and with well-characterized 
tumour promoting roles. Network analysis 
highlighted the central role for EGFR activation in 
mediating the observed responses to MAC 
exposure. Overall, the study sheds light on the 
mechanisms by which sublytic MAC causes 
tumour cell responses and exposes a gene 
expression signature that implicates MAC as a 
driver of tumour progression. These findings have 
implications for understanding of the roles of C 
and the MAC in tumour development and 
progression which in turn will inform future 
therapeutic strategies in cancer.   
________________________________________ 
Inflammation is now well established as a 
crucial contributor in the development and 
progression of tumours; indeed, it has been 
included among the second generation hallmarks 
of cancer (1). A key player in inflammatory 
responses is the complement (C) system, an innate 
immune effector with important roles in defence 
against infection. C provides recognition, early 
warning signals and the initial fast response upon 
exposure to foreign organisms and has evolved to 
amplify the response to the initial signal (2). C 
comprises three activation pathways which 
converge on a common terminal pathway at the 
stage of C5 cleavage; release of a 74 amino acid 
peptide C5a, which has potent anaphylatoxic and 
chemotactic activities (3), leaves the large 
fragment, C5b, to form the nidus of a membrane-
associated complex. Sequential recruitment of C6, 
C7, C8 and multiple C9 molecules creates a 
membrane-spanning pore-like cylindrical protein 
structure known as the membrane attack complex 
(MAC). The MAC can cause osmotic lysis of 
certain susceptible bacteria and of metabolically 
inert cells (4); however, lysis of self-cells is 
restricted by a combination of regulatory proteins, 
ion pumps and MAC removal processes (5). Non-
lytic MAC triggers numerous activation events in 
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cells that likely contribute to the pro-inflammatory 
activity of C (6).  
C has been strongly implicated as an 
effector in tumour clearance over the past 20 
years, largely because of the success of 
monoclonal antibody (mAb)-based 
immunotherapies, many of which are designed to 
harness C as an effector to cause killing of tumour 
cells (7). In this context, the mAb triggers 
overwhelming C activation and tumour cell 
destruction; however, the role of C in tumour 
clearance in the absence of an activating mAb is 
much less clear. Indeed, it has been suggested that 
C activation has a tumour promoting role in many 
malignancies (8). C activation is known to occur 
on tumour cells both in vitro and in vivo in many 
malignancies, including breast (9), papillary 
thyroid (10,11), colorectal (12) and ovarian (13) 
cancers. The best evidence implicating a C 
activation product as a promoter of tumour 
development was provided by the demonstration 
that locally generated C5a recruits myeloid-
derived suppressor cells (MDSCs) into the tumour 
where they suppress the anti-tumour activity of 
CD8+ T-cells (14,15). Others have implicated C5a 
as a factor influencing the balance between tumour 
promotion and tumour clearance (16), while both 
C3a and C5a have been shown to cause 
proliferation in tumour cells, for example in 
neuroblastoma (17,18). Studies in knockout mice 
lacking C3 or C4 confirm important roles for C in 
tumourogenesis, tumour growth being restricted in 
both C3 and C4 knockouts (14). Despite the large 
and growing body of evidence supporting a 
tumour promoting role of C activation (18-21), the 
role of MAC in tumour biology has been 
neglected. 
Most tumours express, and indeed often 
over-express membrane bound C regulators CD55, 
CD59 and CD46 (22). As a consequence, although 
C is activated in the tumour micro-environment, 
activation will be restricted and thus terminal 
pathway activation and MAC deposition may be 
insufficient to kill the tumour cell. Nevertheless, 
MAC deposition on tumour cells at a sublytic level 
may have a profound impact on the target, for 
example by causing an immediate increase in 
intracellular Ca2+ (23) and downstream activation 
of signalling cascades (24). Effects of sublytic 
MAC on cells in vitro include: release of 
inflammatory mediators such as ROS/RNS, 
leukotrienes, arachidonic acid metabolites and 
prostaglandins (5); the release of cytokines such as 
IL-1, TNF α, IL-8, IL-6 and MCP-1 (25); 
increased expression of adhesion molecules such 
as E-selectin, ICAM-1, VCAM-1 and ELAM-1 
(26); release of growth factors such as bFGF, 
PDGF, EGF, PIGF and RANTES (27,28); 
secretion of extracellular matrix (ECM) 
components such as collagen IV and fibronectin 
(29) and regulators such as MMP2 and MMP9 
(30); increased cell proliferation (31); accelerated 
or inhibited apoptosis (32-34) and activation of the 
NLRP3 inflammasome (35). Given this catalogue 
of effects on cell function, it is likely that sublytic 
MAC will significantly influence tumour cell fate 
in vivo. Here we take a novel approach to 
addressing how MAC influences tumour cell fate 
by adopting an unbiased systems analysis of the 
effects of sublytic MAC on the patterns of gene 
expression in a tumour cell, we identify key 
pathways implicated and discuss the impact that 
these might have on tumour survival. 
RESULTS 
Sublytic C attack and MAC inhibition on 
tumour cell lines- The C5-binding protein OmCI 
has been extensively characterised and shown to 
specifically block formation of MAC in human 
and rodent plasma (36,37). The dose of OmCI 
required to completely block MAC formation was 
titrated by assessing inhibition of haemolysis of 
ShEA exposed to pNHS, an assay where target 
haemolysis is absolutely dependent on MAC 
formation (Fig1A). At 10 μg/ml, OmCI caused 
complete inhibition of pNHS induced haemolysis. 
This dose was used in all subsequent experiments. 
The sensitivity of each of the selected tumour cell 
lines, CT26 and B16, to pNHS-induced CDC was 
determined in a calcein release assay immediately 
prior to each experiment. Both CT26 and B16 cells 
were efficiently killed by pNHS without need for 
sensitisation, calcein release correlating with dose 
of pNHS (Fig1B). The dose of pNHS causing 
<10% specific calcein release at 1 hour was 
chosen as the maximum sublytic dose for the 
subsequent experiments. The 1 hour timepoint was 
chosen based on our previous work showing that 
MAC killing of nucleated cell targets is an acute 
event and does not increase further with prolonged 
incubation (6). In order to identify MAC-specific 
effects, cells were also exposed to the same 
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sublytic dose of pNHS but preincubated with the 
inhibitory dose of OmCI (10 μg/mL) to block 
MAC formation. 
Preliminary qPCR experiments were 
carried out on RNA harvested from CT26 cells 
used in the above experiments in order to validate 
targets for subsequent microarray expression 
analyses and determine optimum time points for 
RNA collection. Initially, RNA was harvested at 1 
hour and expression of osteopontin (OPN), a 
candidate gene chosen based on evidence from the 
literature (38), was measured by qPCR. Relative 
expression of OPN increased more in response to 
treatment with pNHS compared to OmCI-treated 
pNHS after 1 hour exposure (Fig1C). To further 
refine the time points of exposure to sublytic MAC 
prior to RNA harvest, the experiment was repeated 
for 6 or 12 hour time points, calculating the 
expression change in relation to untreated cells. 
OPN expression increased significantly at 6 
(p<0.01) and 12 (p<0.05) hours in MAC-exposed 
cells compared to the OmCI control (Fig. 1D). For 
expression analysis, we chose to use 1 hour as an 
initial time point to capture an immediate response 
and 12 hours to capture sustained changes. 
Global gene expression analysis of 
sublytic C- For microarray analysis cells were 
exposed to sublytic C attack and compared to a 
MAC-inhibited control as established in the 
optimisation experiments described above: CT26 
cells seeded at 1.6×103/mm2 were exposed to 5% 
pNHS with or without addition of OmCI, then 
incubated for 1 or 12 hours (4 replicates of each 
condition in wells of a 12-well plate) prior to 
harvest of RNA. RNA was also harvested from 
untreated control cells (4 replicates) to establish a 
baseline. A total of 16 samples were used for 
microarray analysis; 3 from each of the 4 serum 
conditions and all 4 untreated controls. Quality 
control of Microarray data was performed using 
principal components analysis (PCA), a method 
used to compress a high content dataset, enabling 
its description with a limited number of 
contributors to variation. PCA allows the effect of 
experimental parameters on the data to be 
observed and identifies data quality issues. Initial 
PCA showed a batch effect which was eliminated 
using the Partek batch remover tool 
(www.partek.com)  to reveal the most important 
components (Fig. 2A). Data were plotted to 
explore the contributions of the top three 
components; PCA#1 and 3 were best correlated 
with time point and serum exposure, and presence 
of OmCI respectively. Batch removal was not 
retained for downstream analysis because the 
robustness of the ANOVA model used rendered it 
unnecessary.   
To better visualise the impact of 
experimental conditions, scatter plots of median 
baseline adjusted data were prepared to compare 
pNHS to pNHS + OmCI at 1 and 12 hours (Fig 
2B(i) & (ii)). This graphical representation 
revealed that, for most parameters, expression 
changes were more apparent 1h after sub-lytic 
attack than at 12h, indicating that in this system 
most of the changes were transient in nature. To 
measure significance of differential gene 
expression in cells exposed to pNHS with or 
without MAC blockade, a 2-way ANOVA model 
was applied using method of moments (39). Gene 
lists were prepared using the ANOVA generated 
fold change (FC) and p-values to identify the most 
significantly differentially expressed (up or down) 
genes at each time point (Table 1).These show 
those genes which altered expression significantly 
(p<0.05), filtered to include genes changing by 
greater than 2-fold at 1 hour or 1.5-fold at 12 
hours; different filters were chosen to reduce the 
disparity in number of differentially expressed 
genes at these timepoints. Five genes were 
upregulated and 1 downregulated at 1 hour post-
exposure, while two genes were upregulated 12 
hours post-exposure with none downregulated. 
This difference in the number of genes 
differentially regulated between the timepoints 
supports the trends shown in the scatter plots, 
substantially more points falling outside the set 
confidence intervals at 1 hour compared to 12 
hours (Fig  2B).  
Identification of secreted effectors induced 
by sublytic C- To provide functional insight into 
the data a new gene list was prepared using less 
stringent thresholds for inclusion by applying the 
following filters to the ANOVA statistics: FC > 1; 
unadjusted p-value cut-off <0.05 for both 1 hour 
and 12 hour comparisons. This latter filter selected 
for MAC-induced upregulation events that were 
apparent at both 1 and 12 hour time points, 
representing sustained changes. To understand the 
interactions between these genes the list was 
interrogated using MetaCore network building 
tools to automatically map genes to a 
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representative component termed the network 
object (NO). The ‘Shortest Path’ algorithm was 
selected and canonical pathways included for 
network building; to interpret the resulting 
network, nodes were arranged to identify the 
starting NOs and their overlapping connections. 
NOs not connected to the main network were 
removed and those groups displaying little 
connectivity to the larger network were pruned. 
The network was then organised by cellular 
location from top to bottom (Fig. 3). The analysis 
revealed four key highly interrelated NOs, co-
regulated by canonical pathways and with roles 
outside of the cell. These represented 4 genes; 
AREG (encoding amphiregulin), MMP3 (encoding 
matrix metalloproteinase-3; mmp-3), MMP13 
(encoding matrix metalloproteinase-13; mmp-13) 
and CXCL1 (encoding chemokine (C-X-C motif) 
ligand 1; cxcl-1) (Table 2). Other highly connected 
NOs of note were EGFR and the AP-1 complex.  
qPCR validation of identified genes - 
Genes identified as differentially expressed by 
microarray were validated using qPCR to provide 
support for further bioinformatic and biochemical 
exploration of their relevance. The four genes 
identified above as secreted effectors during 
network analysis were selected (Table 2), together 
with four genes identified as showing the most 
significant differential expression (up or down at 
either time point) between MAC-exposed and 
MAC-inhibited pNHS-exposed CT26 cells when 
stringent thresholds were applied (Table 1). 
FAM110c (encoding Family With Sequence 
Similarity 110, Member C) and RGS16 (encoding 
Regulator of G-protein Signalling 16) were both 
increased at 1 hour post-attack; IRF1 (encoding 
Interferon Regulatory Factor 1) was decreased at 1 
hour; HBB-BH1 (encoding Hemoglobin Z, beta-
like embryonic chain) was increased at 12 hours. 
For each of these eight genes, qPCR was 
performed twice, first on cDNA prepared from 
RNA extracted for the microarray experiment and 
second on RNA from a fresh replication 
experiment. The qPCR expression data was 
replicated in these experiments and largely 
confirmed the expression patterns found in 
microarray for these same genes; data are 
presented together for comparison (Fig 4 and 5). In 
a few instances, qPCR and microarray data did not 
completely replicate: CXCL1 showed highest 
upregulation at 1 hour by microarray but at 12 
hours by qPCR; RGS16 peak upregulation at 1 
hour in microarray was confirmed by qPCR using 
the same original RNA but in RNA from the 
second experiment, further upregulation was seen 
at 12 hours post exposure. Despite these minor 
differences, the data strongly correlated, 
confirming the capacity of the microarray to 
accurately detect expression changes.    
To explore whether the observed 
expression changes were cell-type specific, RNA 
extracted from MAC-exposed and control B16 
melanoma cells was analysed by qPCR for 
expression of the four network identified hits, 
AREG, MMP3, MMP13 and CXCL1. Expression 
of MMP3 RNA was negligible in this cell type. 
Expression of RNA for both AREG and CXCL1 
was markedly increased in MAC-exposed cells at 
both 1 and 12 hours, replicating the results 
obtained in CT26 cells (Figure 5). MMP13 RNA 
expression was low in B16 cells and not 
significantly different between MAC exposed and 
control cells.  
Inter-connectivity of secreted effectors and 
regulatory genes- In an effort to identify pathways 
and mechanisms by which MAC effected changes 
in expression of the identified genes, a model was 
developed that analysed the combination of those 
genes identified as significantly differentially 
expressed under stringent statistics and those 
identified by network analysis as downstream 
secreted factors. Figure 6 shows the ‘Shortest 
Path’ network generated using the gene lists 
shown in Tables 1 and 2 as input. The main hub of 
the network contained 11 of the total 12 starting 
NOs; FAM110C, ITPRIP and HBB-BH1 were 
unconnected and therefore hidden. The network 
shows that the starting 11 NOs are well connected 
with a central triangle containing EGR1, EGR2 
and IRF1, suggesting they are key drivers of the 
gene expression response to MAC. NOs added by 
the algorithm included AP-1 transcription factor 
subunit c-JUN, several NFkB subunits, the 
glucocorticoid receptor-alpha, c-Myc and the 
epidermal growth factor receptor (EGFR).  Ap-1 
and NFkB are the only two transcription factor 
NOs connected to all 4 secreted NOs validated by 
qPCR. 
Transcriptional regulation network - In 
order to interrogate the data further and explore 
transcription regulation patterns from a greater 
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number of data points, a gene list was generated 
by applying an FDR adjusted p-value cut-off of 
<0.05 to the ANOVA statistics for the pNHS vs. 
pNHS+OmCI comparison. This was applied 
separately for 1 hour and 12 hour time points and 
the two lists combined to identify the most 
significant MAC induced expression changes at 
either time point and regardless of direction. This 
new list was combined with that created to 
generate figure 3 and the entire genelist uploaded 
to MetaCore (https://portal.genego.com/). The list 
was used as the starting list for the Analyze 
Network (transcription factors) (AN(tf)) algorithm 
applied using the default settings.  
The AN(tf) algorithm identifies 
transcription factors for which there are enriched 
numbers of targets in the starting list, then uses the 
list to find the shortest path back to a receptor for 
which there are ligands in the starting list, thereby 
creating networks for each transcription factor, 
ranked by significance, based on enrichment of 
starting NOs via calculated g-scores, z-scores and 
p-values. z-score indicates the saturation of 
starting NOs, the g-score is a modified z-score 
describing the number of Canonical Pathways 
used to build the network; p-Value assesses the 
probability of the number of starting NOs falling 
on the generated network by chance accounting for 
the total number of NOs in the network and in the 
entire database (40). 
The network with the highest g-score, z-
score and smallest p-value was selected: g & z-
scores = 187.12, p-value = 7×10-211. To assist in 
interpretation, the network was organised by 
aligning the most connected NOs in the centre and 
placing the remaining NOs by protein class and in 
context around these main hubs (Fig. 7). With c-
Myc and CREB1 as the main controlling 
transcription factors, EGFR and TrkB are 
introduced as non-seed nodes to the network as 
putative receptor starting points with EGFR the 
most interacting of the two. Other important TF 
hubs include c-jun. p53, ESR1, and Oct3/4. All 
four secreted effectors identified in microarray are 
present and the NO with most direct connections 
with these is c-Jun. Other signalling molecules 
with high connectivity include AKT and ERK1/2. 
The network contains 6 of the 8 validated genes. 
Overall the AN(tf) network includes 67 of the 118 
candidate objects and provides evidence for a 
central role of EGFR activation by sublytic MAC. 
DISCUSSION 
The role of C as a tumour promoter has 
attracted a great deal of attention over the last few 
years because of evidence for significant C 
activation in diverse tumours. MAC is suspected 
to be influential given its published activating and 
proliferative effects on nucleated cells (5,6,14); 
however, signalling mechanisms underlying many 
of these effects remain ill defined. We took a 
novel approach to understanding the role of the 
MAC, taking advantage of an available terminal 
pathway inhibitor, global gene expression 
technology and systems biology methodology. 
Sublytic conditions were optimised using pNHS as 
a C source and OmCI to block terminal pathway 
activation. CT26 colon carcinoma cells were 
selected as a model tumour cell and MAC-specific 
gene expression changes mapped by microarray, 
qPCR and network analysis. These approaches 
revealed a gene expression pattern in tumour cells 
exposed to sublytic MAC which could 
significantly impact cell survival and proliferation 
as well as reshape surrounding ECM. The key 
findings were replicated in an unrelated tumour 
cell line, B16 melanoma. 
Statistical analysis of array data 
comparing MAC exposed cells with controls 
confirmed a set of expression changes; genes 
involved in Ca2+ and G-protein signal transduction 
(ITPRIP, RGS16), early response transcription 
factors (EGR1, EGR2), and inflammatory 
responses (IRF1) were significantly altered. 
Network analysis to map the interactions of genes 
upregulated at the 1 hour and 12 hour time points 
highlighted 4 further expression changes in genes 
encoding proteins with extracellular localization, 
AREG, CXCL1, MMP3 and MMP13 genes; these 
were co-regulated by putative canonical signalling 
cascades including PKC, PI3k/AKT, JNK, Erk1/2 
and p38. 
The product of the AREG gene is the 
amphiregulin protein (AR), an EGF-like ligand 
capable of  triggering erbB2 activation (41). 
CXCL1 ligand is a potent neutrophil 
chemoattractant, important in infection and signals 
via CXCR2, a G-protein coupled receptor (42). 
MMP3 and MMP13 both code for matrix 
metalloproteinases (MMPs) that function in 
extracellular matrix regulation and remodelling; 
they are important during development, wound 
healing, proliferation and inflammation (43). 
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Validation by qPCR confirmed that the 
expression changes highlighted in gene array and 
supported by statistics and network building were 
real and robust. Critically, expression changes for 
two of these genes, AREG and CXCL1 closely 
replicated in an unrelated tumour cell line, B16. 
MMP expression in this line was extremely low so 
changes could not be replicated.  
Network generation using these and the 
remaining statistically significant changes found 
interactions between all identified genes apart 
from FAM110C and highlighted the central 
importance of IRF1, EGR1, and EGR2 in 
mediating the changes. EGFR is noteworthy in 
that it is placed in between two starting NOs, 
Amphiregulin and Rgs16, the three connected in 
an extracellular to nuclear direction, supportive of 
EGFR activation. Rgs16 is further connected to 
Egr1, Egr2 and Irf1 via c-Myc. Egr1 protein is 
known to positively regulate EGR2 gene 
expression, while Egr2 protein negatively 
regulates EGR1 (44,45); Egr1 protein is reported 
to inhibit IRF1 expression (46). AP-1 and NFκB 
were both highlighted as possible transcriptional 
regulators in the network. The AP-1 and NFkB 
complexes are known to regulate MMP3, MMP13 
and CXCL1 gene expression in mouse and human 
cells (47-52).  
Ap-1 (a heterodimer of c-fos and c-jun) 
and NFκB  are known to be responsive to MAC 
(53) and have been cited as important regulators of 
the response to sublytic C (6). In particular, c-fos 
is upregulated rapidly in MAC-exposed cells and 
is linked to Ca2+ flux and MAPK (particularly 
ERK) involvement (54). MMP3 and MMP13 
upregulation has been described in MAC-attacked 
chondrocytes in human disease and an 
experimental model of osteoarthritis (55). Each of 
the canonical signalling cascades identified in the 
network, PKC, PI3k/AKT, JNK, Erk1/2 and p38 
have been reported to be activated in cells exposed 
to sublytic MAC (6). 
The larger network generated using genes 
significantly changed either at 1 or 12 hours 
exposure alongside those upregulated at both time 
points provided greater insight into mechanisms 
responsible for observed gene expression changes 
in CT26 cells. The network placed EGFR central 
in the response, an assignment supported by the 
presence of this receptor in all three generated 
networks (Fig 7). EGFR is a member of the erbB 
receptor tyrosine kinase (RTK) family, activated 
by ligand binding at the cell surface triggering 
phosphorylation of the intracellular tyrosine kinase 
domain (56). Activation of the EGFR system has 
also been described in response to cellular 
stressors such as UV,  osmotic and oxidative stress 
(57). MAC may cause analogous stress responses; 
indeed, there is evidence that it can induce 
expression of the EGF ligand and cause EGFR 
signalling activation without ligand binding (58). 
The response may involve Gαi protein activation 
independent of receptor, which is known to be 
activated by MAC (59). Indeed, our data showing 
an RGS16 expression response to MAC supports 
this assertion; RGS16 gene expression is induced 
as a feedback mechanism for G-protein signalling 
(60). MAC can transactivate several other RTKs, 
including fibroblast growth factor receptor-2 
(FGFR2), and hepatocyte growth factor receptor 
(HGFR) (58). Potentiation of EGFR activation 
may come from MMP cleavage and release of 
EGF family ligands such as HB-EGF at the cell 
surface, a pathway supported by our demonstration 
of AREG upregulation (61). 
Increased expression of AREG, CXCL1, 
MMP3 and MMP13 is described at mRNA and 
protein levels in a number of human cancers such 
as breast, colorectal, ovarian and pancreatic (62-
69). This increased expression of the four effector 
genes often correlates with tumour development 
and aggressivity, and can be predictive of patient 
prognosis (70-72). Their activities promote cell 
proliferation, activation and motility through 
various mechanisms. AREG contributes to 
tumourigenesis via its function as a growth factor, 
the development of autocrine or juxtacrine loops 
that promote cell proliferation and survival. and 
increased cell motility (63,71), CXCL1 acts 
through  recruitment  of myeloid-derived 
suppressor cells to the tumour microenvironment 
where they support tumour growth and metastasis 
and suppress the local immune response (70). 
MMP family members contribute through their 
role in regulating the ECM (73), promoting 
angiogenesis, tumour invasion and metastasis (72). 
In addition they cleave and activate molecules in 
ECM which promote proliferation, motility and 
induce alterations in adhesion (74). Increased 
expression of MMPs is associated with poor 
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poor prognosis, increased likelihood of metastasis 
and shorter survival time (72). In particular, 
MMP3 promotes tumour progression by 
releasing/activating E-cadherin, L-selectin, HB-
EGF and TNFα and is  described as a central 
mediator of mammary tumourigenesis (69). 
MMP3 is reported to induce a stable epithelial to 
mesenchymal transition, a process which is closely 
linked to tumour development (75). MMP13 
contribution to tumour promotion is mainly 
through its pro-angiogenic activity, increasing 
vascular density in tumours (76). Together, 
alterations in the expression of these four genes 
represent a powerful influence on tumour 
development. Induction of expression of these 
genes in response to MAC may therefore indicate 
a tumour promoting role. 
A role for C as a tumour promoting 
system has recently gained mainstream recognition 
(19). The work presented here represents a novel 
approach to uncover this relationship, using global 
expression data and systems biology analysis to 
explore both the mechanisms and the 
characteristics of such a response. The approach 
has provided evidence to suggest that MAC 
deposition which does not result in cell lysis is a 
potent tumour cell activator leading to significant 
changes in gene expression in several critical and 
interlinked pathways. These data fit well with 
published piecemeal studies in diverse cell types. 
The work not only sheds light on the signalling 
cascades and responsive transcription factor 
systems that respond to MAC but also reveals a 
downstream gene expression response to MAC 
which will alter tumour behaviour through 
induction of proliferative, migratory and survival 
pathways. Interestingly, a central role for the 
EGFR system was identified, although it was not 
clear whether this was activated directly by MAC 
or indirectly following MAC exposure. Overall, 
this work provides additional evidence implicating 
sublytic MAC in tumour cell activation and has 
implications not only for our understanding of the 
tumour promoting effects of C but also for new 
approaches to cancer therapy. 
EXPERIMENTAL PROCEDURES 
Materials- Pooled normal human serum 
(pNHS) was obtained from whole blood collected 
from consenting volunteers. Blood was placed in 
20 mL glass vials and allowed to clot. Serum was 
separated by centrifugation, pooled, 0.22 µm 
filtered and stored in aliquots at -80°C. Sheep 
erythrocytes (ShE) in Alsever’s solution were 
purchased from; TCS Biosciences (Buckingham, 
UK). Complement fixation diluent (CFD) was 
from Oxoid (Basingstoke, UK). Anti-ShE 
antiserum (Amboceptor) was from Siemens 
(Forchheim, Germany). CT26 mouse colon 
carcinoma and B16 mouse melanoma cell lines 
were from American Type Culture Collection 
(ATCC, Manassas VA, USA). RPMI 1640 
medium (RPMI), fetal bovine serum (FBS) and 
additives and calcein-AM were obtained from 
Invitrogen (Paisley, UK). Complete medium 
comprised RPMI 1640 with 5% heat-inactivated 
FBS. All other chemicals were from Sigma 
Aldrich (Gillingham, UK). 
Preparation of antibody sensitised sheep 
erythrocytes (ShEA)- ShE were washed into CFD 
and re-suspended at 4% (v:v) in CFD (10ml total 
volume) at 37°C.  Amboceptor, diluted 1:2000 in 
10ml of CFD, was mixed with the ShE suspension 
and incubated for 30 minutes at 37°C. The 
resultant ShEA were washed and diluted to 2% 
(v:v) in CFD.  
Haemolytic assay- Haemolytic activity in 
pNHS was used as a measure of MAC formation, 
assessed by incubating (37oC for 60 min) triplicate 
serum dilutions in CFD with an equal volume of 
ShEA in wells of a 96-well plate. No serum (CFD 
alone) and 100% lysis (CFD containing 0.1% 
triton-X-100) controls in triplicate were included. 
Plates were spun, supernatant transferred to a flat 
bottomed 96 well-plate and absorbance measured 
at 410 nm using a FLUOstar OPTIMA plate reader 
(BMG Labtech, Aylesbury, UK). Percentage 
haemolysis was calculated using the equation: 
% ����� = ቆ�௖௢௠௣௟௘௠௘௡௧ ௥௘௟௘�௦௘ − �௦௣௢௡௧�௡௘௢௨௦ ௥௘௟௘�௦௘�ௗ௘௧௘௥�௘௡௧ ௥௘௟௘�௦௘ − �௦௣௢௡௧�௡௘௢௨௦ ௥௘௟௘�௦௘ ቇ × ͳͲͲ 
To titrate the effect of the C5 inhibitor 
Ornithodoros moubata C inhibitor (OmCI; gift of 
Dr. Miles Nunn) on MAC formation and 
haemolytic activity, aliquots of pNHS were pre-
incubated with different doses of OmCI prior to 
measurement of haemolysis as above.  
Complement-directed cytoxicity (CDC) 
assay- We chose the well-described calcein release 
assay to measure tumour cell killing. The cell-
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permeant calcein AM is taken into cells and 
trapped by de-esterification to calcein; release of 
calcein from the cells then correlates with lytic cell 
death.  CT26 cells or B16 cells were grown as 
monolayers in complete medium to 80% 
confluence in 75 cm2 TC flasks then washed in 
saline and harvested by incubation in 10mM 
EDTA in PBS (30min). Harvested cells were 
washed in RPMI, diluted to a density of 5×105 
cells per mL in complete medium, aliquoted at 100 
µL/well into flat-bottomed 96 well-plates, and 
incubated for 16 hours at 37°C, 5% CO2. Adherent 
cells were washed and 100 µL complete medium 
containing 2 µg/mL calcein AM was dispensed 
into each well. Plates were incubated for 1 hour at 
37°C, 5% CO2. Calcein-loaded cell monolayers 
were washed twice in RPMI, then pNHS dilutions 
(0-40% in 100 µL RPMI) dispensed directly into 
wells and incubated for a further 1 hour at 37°C, 
5% CO2. Supernatants were transferred to fresh 
96-well plates and fluorescence measured (EX 
485nm EM 520nm) in a Fluostar Optima plate 
reader. Remaining cells were lysed by addition of 
100 µL 0.2 % Triton-X-100 in RPMI per well and 
released fluorescence measured as above. 
Percentage lysis was calculated using the 
following equation (FI = fluorescence intensity):  % ����� = ͳͲͲ × ሺ��௖௢௠௣௟௘௠௘௡௧ ௥௘௟௘�௦௘/ሺ��௖௢௠௣௟௘௠௘௡௧ ௥௘௟௘�௦௘ + ��ௗ௘௧௘௥�௘௡௧ ௥௘௟௘�௦௘ሻ). 
Titrating sublytic C attack- CT26 or B16 
cell monolayers were washed with saline then 
incubated (37°C, 5% CO2, 1h or 12 h) with pNHS 
at a dilution previously titrated to give less than 
10% lysis at 1 hour, a timepoint when maximum 
lytic killing has been reached, either in the 
presence or absence of a dose of OmCI that 
completely inhibited haemolytic activity [10 
μg/ml]. Monolayers were washed in RPMI and 
RNA harvested using the Genelute Mammalian 
Total RNA Miniprep Kit (Sigma-Aldrich). 
Global gene expression analysis- RNA 
concentration and quality were measured using the 
Agilent 2100 Bioanalyzer (Agilent Technologies, 
Stockport, UK) and global gene expression 
analyses performed on the Illumina Microarray 
platform (Illumina, Saffron Walden, UK; Cardiff 
University Central Biotechnology Services). 
Amplification of material to generate cRNA and 
labelling was carried out according to 
manufacturer’s instructions. Hybridisation 
experiments were performed using the mouse 
ref8v2 BeadChips (2 X 8 samples) and analysed 
using the iScan Reader and Control Software 
(Illumina). GenomeStudio Expression Module 
software (lllumina) was used to convert signal 
intensity data into expression data. Data were 
normalized using the quantile method and log 
transformed (77). Principal components analysis 
(PCA) and primary statistical analysis were 
performed using PartekGenomics Suite version 6.6 
(build 6.13.0213, Partek Inc., Missouri, USA) and 
graphical representations obtained using 
GeneSpring 12.0 GX (Agilent Technologies). 
Pathway analysis was performed using MetaCore 
software (Thomson Reuters, London, UK). 
QPCR analysis of mRNA- To validate 
differences in the relative expression of genes of 
interest implicated from gene expression analysis, 
extracted RNA samples (1 µg) were reverse 
transcribed using TaqMan Reverse Transcription 
Reagents (Applied Biosystems, Paisley, UK) 
following manufacturer’s instructions; resulting 
cDNA was stored at -80°C. For qPCR, sufficient 
cDNA for triplicate reactions of each primer pair 
diluted 1/10 in ultrapure H2O, was mixed with 1× 
SYBR Green Jump Start Readymix (Sigma-
Aldrich, Dorset, UK) according to manufacturer’s 
instructions. Reaction mixes were aliquoted into 
48-well white PCR plates, sealed with optical flat 
8-cap strips (Bio-Rad, Hertfordshire, UK) and 
placed in a MiniOpticon Real-Time PCR System 
(Bio-Rad) controlled using the Opticon Monitor 
3.1 software. Thermocycling was adjusted from 
the manufacturer’s protocol (65°C annealing 
temperature and 40 cycles) to take account of 
relative expression, assessed using the ΔΔCt 
method where calculated Ct was the cycle number 
at which fluorescence crossed a threshold level 
selected as the point where PCR expansion was 
linear in all samples. The mean Ct values for the 
housekeeping genes β-actin and Polr2A were 
assessed, ΔΔCt calculated for each sample and 
results expressed as a percentage of the control. 
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FOOT NOTES  
The abbreviations used are: C, Complement; MAC, membrane attack complex; ECM, extracellular 
matrix; ShE, sheep erythrocytes; CFD, complement fixation diluent; pNHS, pooled normal human serum; 
CDC, complement dependent cytotoxicity; AN(tf), analyze network (transcription factor); NO, network 
object; EMT, epithelial mesenchymal transition, EGFR, epidermal growth factor; MMP, matrix 
metalloproteinase.  




FIGURE 1. Optimization of sublytic complement conditions. A. Haemolytic activity testing lysis of 
ShEA by serum with or without 10 µg/mL OmCI (C5 blocker), titrated from 16% down to 0%. B. 
Susceptibility of CT26 cells to C lysis; cells in a monolayer were loaded with calcein AM then exposed to 
serum for 1h at 37°C. Lysis was calculated from the release of calcein into the supernatant and expressed 
as the percentage of the total entrapped calcein obtained by detergent lysis of the cells. Results are means 
of 4 separate experiments +/- SEM. C&D. Expression analysis of OPN in CT26 cells in response to 
exposure to sublytic C for 1, 6 and 12 hours. CT26 cells were exposed for 1 (i), 6 and 12 (ii) hours to 5% 
serum treated with or without a MAC-blocking dose of OmCI and OPN gene expression analysed by 
qPCR. Expression was calculated as % of untreated control (ii). Results are means of 3 determinations +/- 
SEM (*p<0.05, **p<0.01).  
 
FIGURE 2. Primary microarray data analysis. A. PCA plot of top three principle components. Three 
dimensional plot showing the top 3 principle components of the microarray data as calculated using 
principle component analysis (PCA). Contributing principle components (PC) are labelled on each axis 
alongside the calculated % contribution to overall variation. Each sample from the experiment is 
represented by a coloured sphere; red=control, green=pNHS, blue=pNHS+OmCI. A centroid sphere 
shows how these samples are grouped according to their experimental conditions; black=control, pale 
blue=OmCI at 1hr, darker blue=OmCI at 12hrs, light green=pNHS at 1hr and darker green=pNHS at 12 
hours. B. Scatter plot comparisons between samples exposed to pNHS and pNHS+OmCI at 1 (i) and 12 
(ii) hours. Log2 transformed, median baseline adjusted data. Expression is presented as distribution 
around a median that represents equal gene expression in the two conditions. The parallel flanking lines 
represent gene expression changes of +/- 1.3-fold change; data points falling outside these lines are 
considered to be differentially expressed. Data points are coloured according to their expression levels 
(median baseline adjusted) upon exposure to pNHS; green=below median, red=above median. 
 
FIGURE 3. Network analysis of overlap gene list. List includes genes upregulated by sublytic MAC at 
both time points. The network was generated in MetaCore using the following options: ‘Shortest Path’ 
network building algorithm with a maximum of 2 steps, and inclusive of canonical pathway; this latter 
option allows sequences of interactions that occur frequently in the cell to be counted as single steps in 
the shortest path. The network describes the interconnected regulation of upregulated genes and highlights 
four key downstream effector genes. The network is organised so that nodes are organized by the sub-
cellular localization of their products, from extracellular to nuclear.  Nodes present in the input list are in 
blue circles. Thick light blue lines highlight the various canonical pathways of signal transduction and 
transcription regulation. Seed nodes are circled in navy blue, lines represent interactions, either 
transcriptional regulation or protein-protein associations; red=inhibition and green=activation. 
 
FIGURE 4. qPCR validation of statistically significant hits. Microarray=original microarray data, 
Primary Validation=RNA extracted in parallel with that used in microarray, Secondary validation=RNA 
extracted in a fresh sublytic attack experiment. RNA was reverse transcribed and FAM110C, RGS16, 
IRF1 and HBB-BH1 gene expression analysed by qPCR and calculated as expression relative to 
housekeeping genes β-actin and Pol2ra using the ΔΔCt calculation then presented as % of untreated 
control. Results are means of 3 determinations +/- SEM (*p<0.05, **p<0.01, ***p<0.001).  
 
FIGURE 5. qPCR validation of network identified hits. Microarray=original microarray data, Primary 
Validation=RNA extracted in parallel with that used in microarray, Secondary validation=RNA extracted 
in a fresh sublytic attack experiment. B16 validation= RNA extracted from fresh sublytic attack 
experiment using the B16 mouse myeloma cell line (MMP3 message was not significantly detected in this 
cell line). In all cases RNA was reverse transcribed and MMP3, MMP13, CXCL1 and AREG gene 
expression analysed by qPCR and calculated as expression relative to housekeeping genes β-actin and 
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Pol2ra using the ΔΔCt calculation then presented as a % of untreated control. Results are means of 3 
determinations +/- SEM (*p<0.05, **p<0.01, ***p<0.001).  
 
FIGURE 6. Network analysis of collated gene list. Network describing the interconnected regulation of 
the four key downstream effector genes as well as the 8 statistically significant genes. The network was 
generated in MetaCore using the following options: ‘Shortest Path’ network building algorithm with a 
maximum of 2 steps, excluding canonical pathways. Network is organised to show cellular localisation 
from extracellular (top) to nucleus (bottom). From the list, ITPRIP, FAM110C and HBB-BH1 are not 
represented on the network due to lack of connectivity. Seed nodes are circled in navy blue, lines 
represent interactions either transcriptional regulation or protein-protein associations; red=inhibition and 
green=activation.  
 
FIGURE 7. Network of transcriptional regulation and ligand receptor signalling.  This network uses a 
greater number of genes, including all those identified as significantly changed by combining 
significantly differentially expressed genes with those significantly upregulated at both time points. The 
network was generated in MetaCore using the following options: ‘Analyze Network (Transcription 
Factors)’ network building algorithm with ‘Add ligands and TF targets’ selected. The algorithm generates 
a list of possible networks, with scores based on the number of seed nodes to non-seed nodes and the 
presence of canonical pathway threads. The network with the highest score for these two factors was 
selected and manually organised, first showing the four validated genes, and then the most highly 
connected objects regardless of functional type, to their right. The remaining objects were sorted by 
function so that TFs, kinases, phosphatases, generic proteins and binding proteins were from left to right. 
Ligands and receptors were placed to the far left. Seed nodes are circled in navy blue, predicted receptor 
trigger is highlighted in green, predicted controlling TF is highlighted in red, lines represent interactions 
either transcriptional regulation or protein-protein associations; red=inhibition and green=activation. 
  






A. Probeset ID Symbol Transcript p-value (pNHS * 1  
vs. OmCI * 1) 
Fold-Change (pNHS * 1  
vs. OmCI * 1) 
1 ILMN_2623983 Egr2 ILMN_212209 4.57E-11 2.08117 
2 ILMN_2600744 Rgs16 ILMN_209950 3.03E-09 2.74759 
3 ILMN_2995794 Itprip ILMN_242056 6.49E-08 2.16089 
4 ILMN_2662926 Egr1 ILMN_215729 9.47E-08 2.37517 
5 ILMN_2757634 Fam110c ILMN_222981 1.89E-07 2.07236 
B. Probeset ID Symbol Transcript p-value (pNHS * 1  
vs. OmCI * 1) 
Fold-Change (pNHS * 1  
vs. OmCI * 1) 
1 ILMN_2834777 Irf1 ILMN_209850 5.15E-10 -2.19138 
C. Probeset ID Symbol Transcript p-value (pNHS * 12  
vs. OmCI * 12) 
Fold-Change (pNHS * 12  
vs. OmCI * 12) 
1 ILMN_1260323 Akr1c18 ILMN_215518 4.16E-07 1.61755 
2 ILMN_1225816 Hbb-bh1 ILMN_216390 1.99E-07 1.58676 
 
TABLE 1. Gene list of top most significant expression changes when comparing pNHS with 
pNHS+OmCI at 1 hour and 12 hours. List criteria: FDR adjusted p-value <0.05 A. pNHS 1 hour relative 
to pNHS+OmCI 1 hour, fold-change (FC)> 2 (upregulated) and B. FC< -2 (down regulated), C. pNHS 12 
hour relative to pNHS+OmCI 12 hour, FC> 1.5. Entities are sorted by p-value and FC displayed (pNHS 









Probeset ID Symbol Transcript 
p-value 
(pNHS * 1  
vs. OmCI * 1) 
Fold-Change 
(pNHS *1  
vs. OmCI * 1) 
p-value 
(pNHS * 12  
vs. OmCI * 12) 
Fold-Change 
(pNHS * 12  
vs. OmCI * 12) 
1  ILMN_1238547  Areg ILMN_217903  2.31E-06 1.43899 0.00185142 1.18086 
2  ILMN_2737685  Mmp13 ILMN_210384 1.06E-06 1.52378 0.0100312 1.14512 
3  ILMN_2753809 Mmp3 ILMN_219123 9.89E-05 1.23906 0.00367792 1.08968 
4  ILMN_2763245 Cxcl1 ILMN_223377 8.74E-03 1.55636 0.0215031 1.45109 
 
TABLE 2. Gene list entities. Areg, Mmp13, Mmp3, Cxcl1 are sorted by p-values at 1 hour and 12 hours 
and fold change displayed (pNHS relative to pNHS+OmCI).  
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Figure 5.  
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Figure 7. 
 
 
 
 
